姜黄素对晚期宫颈癌患者Bcl-xL、Bcl-2、EphA2及EphrinA1表达的影响  

Effects of Curcumin on EphrinA1, Bcl-2, EphA2 and Bcl-xL in Patients with Advaned Cervical Cancer

作　　者：李季[1] 邹波峰[1] 王远鹤[1] 阮有民 刘恒 

机构地区：[1]辽宁省肿瘤医院肿瘤科,辽宁沈阳110042 [2]辽河油田总医院渤海院区肿瘤诊治中心肿瘤科,辽宁盘锦124010

出　　处：《现代生物医学进展》2016年第7期1314-1317,共4页Progress in Modern Biomedicine

基　　金：辽宁省科技厅自然科学基金资助项目(20032111)

摘　　要：目的:探究姜黄素对宫颈癌晚期放疗患者Bcl-x L、Bcl-2、Eph A2与Ephrin A1表达的影响。方法:收集160例晚期宫颈癌放疗患者的宫颈癌石蜡标本,分为姜黄素组与对照组,均给予放射治疗,姜黄素组放疗期间加服姜黄素片剂,采用免疫组化等实验方法,观察两组病例标本Bcl-x L、Bcl-2、Eph A2与Ephrin A1的表达情况,比较两组病理标本化疗前后的凋亡细胞指数(AI)与微血管密度(MVD)。结果:姜黄素组的Bcl-x L、Bcl-2、Eph A2与Ephrin A1的表达阳性率分别为8.3%、43.33%、46.67%、15.0%,均显著低于对照组(P<0.05);放疗后姜黄素组的AI显著高于对照组(P<0.05),MVD显著低于对照组(P<0.05)。结论:姜黄素可抑制Bcl-x L、Bcl-2的表达以促进肿瘤细胞凋亡,同时降低Eph A2与Ephrin A1的表达以减少肿瘤微血管形成,有显著的抗肿瘤与放疗增敏作用。Objective： To investigate the effect of curcumin on the expression of Ephrin A1, Eph A2, Bcl-2 and Bcl-x L in patients with cervical cancer in advanced stage. Methods： The paraffin specimens of 160 cases of advanced cervical carcinoma treated with radiotherapy were collected and divided into curcumin group and control group. The two groups were treated with radiotherapy, while the curcumin group was treated with curcuminand. The expression of Ephrin A1, Eph A2, Bcl-2 and Bcl-x L were observed in the two groups through the experimental method. The apoptotic cell index（AI） and microvessel density（MVD） were compared between the two groups.Results： The positive rate of Ephrin A1, Eph A2, Bcl-2 and Bcl-x L was 8.3 %, 43.33 %, 15 %, 46.67 %, 8.3 %, respectively, significantly lower than that in the control group（P0.05）, respectively. AI was significantly higher than that in the control group（P0.05）, and MVD was significantly lower than that in the control group（P0.05）. Conclusions： Curcumin can inhibit the expression of Bcl-x L and Bcl-2 in order to promote tumor cell apoptosis, and decrease the expression of Eph A2 and Ephrin A1 in order to reduce tumor angiogenesis, and has a significant effect on antitumor and radiotherapy.

关 键 词：晚期宫颈癌 放疗 姜黄素 基因表达 

分 类 号：R737.33[医药卫生—肿瘤]